Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients

poor prognosis, with hazard ratio 4.08 (95% confidence interval [CI], 1.62-10.28), 9.93 (95% CI, 3.51-28.13), and 11.23 (95% CI, 3.34-37.83), respectively. Luminal A subtype was the only intrinsic subtype in which higher NLR patients showed significantly poor prognosis (87.7% vs. 96.7%, p= 0.009). Conclusion: Patients with an elevated pretreatment NLR showed poorer diseasespecific survival than patients without elevated NLR, most evi dent in the luminal A subtype. Further validation and a feasibility study are required before it can be considered for clinical use.